Gsk (GSK) Non Operating Interest Expenses (2009 - 2026)

Gsk's Non Operating Interest Expenses history runs 18 years deep, the most recent figure standing at -$244.2 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 0.52% year-over-year to -$244.2 million; the TTM figure through Jun 2026 stood at -$1.6 billion (down 7.7% YoY), while the FY2021 annual figure was $26.1 million, down 24.6% from the prior year.
• Non Operating Interest Expenses for Q2 2026 stood at -$244.2 million, down from -$225.1 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was -$202.7 million in Q3 2024, with the low at -$1.0 billion in Q4 2022.
• The 5-year median for Non Operating Interest Expenses is -$239.9 million (2022), against an average of -$392.1 million.
• The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses advanced 14.66% in 2024, then fell 11.76% in 2025.
• Gsk's Non Operating Interest Expenses stood at -$1.0 billion in 2022, then advanced by 4.66% to -$983.0 million in 2023, then climbed by 12.65% to -$858.7 million in 2024, then dropped by 8.59% to -$932.4 million in 2025, then surged by 73.81% to -$244.2 million in 2026.
• Business Quant data shows GSK's Non Operating Interest Expenses at -$244.2 million in Q2 2026, -$225.1 million in Q1 2026, and -$932.4 million in Q4 2025.